’Orphan drug’ rule raises off-label worries for drugmakers

The U.S. Department of Health and Human Services last week clarified when hospitals are allowed to buy socalled orphan drugs at sharply discounted prices, but it left open questions for drug manufacturers about the risk of being prosecuted for off-label promotion of them.

The drugs, which are for rare diseases and named after the small “orphan” populations of fewer than 200,000 people they’re designed to treat, are among the most expensive on the market.

Originally published in Thomson Reuters on 7/31/13.

Please see full alert below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Below-Cost Pricing, Healthcare, HHS, Hospitals, HRSA, Off-Label Promotion, Off-Label Use, Orphan Drugs, Pharmaceutical, Prescription Drugs

Published In: Health Updates, Insurance Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Mintz Levin - Health Law & Policy Matters | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »